Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years?
Viking Therapeutics (NASDAQ: VKTX) is a healthcare company that possesses a lot of growth potential. And last year, its shares rose by 116%, as investors were bullish on its prospects.
This year, however, has been a much different story, with the markets on shaky ground. Viking has lost more than 40% of its value since January.
While there has been some significant volatility in the short term, there could still be a lot more room for Viking to be a much more valuable business in the long run, especially if it ends up having a top GLP-1 weight loss drug in its portfolio. Could Viking become one of the top healthcare stocks in the world in 10 years?
It's not hard to see why this company, which currently has a market cap of around $2.5 billion, can become a lot more valuable in the future. VK2735 is a drug candidate in Viking's portfolio that has been showing some exciting results in clinical trials. It has helped people lose around 15% of their body weight in a phase 2 trial. The company has also been developing an oral version of the drug, which helped people achieve at least 5% weight loss after about a month of being on the pill -- based on a phase 1 trial.
Then there's VK2809, a possible treatment for MASH, a form of nonalcoholic fatty liver disease. In a phase 2 trial, it was able to reduce liver fat after a period of 52 weeks by an average of 37% to 55%.
Between VK2809 and VK2735, there could easily be billions of dollars in revenue for Viking to bring in, as both drugs could be blockbusters. The caveat, however, is that there's still a fair bit of uncertainty ahead, as there's no guarantee they will be approved. It will be costly to continue to develop these drugs and to commercialize them, should they obtain approval.
Even under the best-case scenario, it could be multiple years before the company sees any revenue from these products. But the potential is certainly there.
If VK2809 and VK2735 obtain approval, there is no doubt in my mind that Viking's valuation will skyrocket and the healthcare stock could double or even triple in value, especially given the exciting potential in GLP-1. But for its upside to be even higher than that, and for the company to be among the most valuable in its industry, I believe it needs to have more assets to build around.
That's because many healthcare companies are investing heavily into GLP-1 drugs in order to not miss out on a market opportunity that may easily be worth more than $100 billion. This includes industry heavyweights such as Pfizer and Roche. And Eli Lilly already has an approved weight loss drug in Zepbound.
Competition is going to be fierce, and having an approved GLP-1 drug may not be enough to make Viking a top healthcare company. Approval of a drug in this space can generate significant returns for investors who buy the stock today, but whether its valuation continues to climb higher will ultimately depend on how diversified and strong its roster of drugs is in the future.
Viking's stock skyrocketed last year amid hopes of supercharged growth for the business, due to its promising GLP-1 drug. But the company also incurred a net loss of $110 million in 2024, and losses are likely to continue for the foreseeable future.
Approval of the drugs listed earlier can help with the business in getting to breakeven and boosting its overall valuation, but that may not be enough to make Viking a top healthcare stock in the future. A lot will depend on what other drugs it ends up developing and bringing to market in the years ahead.
However, at its reduced valuation, I see a lot of good value in Viking's stock, given the potentially lucrative, moneymaking assets it has in its portfolio. This is a stock that may be worth investing a modest amount of money into, assuming that you're comfortable with the risk and uncertainty that comes with it.
It's hard to predict which companies will become big players within their industries in a decade, but by putting money into multiple promising growth stocks, you can increase the odds for success that one of your investments may be a big winner over the long term. Viking does have that potential, even though it is by no means a sure thing. It's an exciting stock to watch, and while it may not be suitable for all types of investors, if you can stomach the risk, it may be worth buying right now.
Before you buy stock in Viking Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $469,399!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $590,231!*
Now, it's worth noting Stock Advisor's total average return is 731% — a market-crushing outperformance compared to 146% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of April 5, 2025
David Jagielski has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Roche Holding AG and Viking Therapeutics. The Motley Fool has a disclosure policy.
Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years? was originally published by The Motley Fool
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Baird Upgrades Urban Outfitters, Inc. (URBN) on Nuuly Growth
Urban Outfitters, Inc. (NASDAQ:URBN) is among the 10 Best Growth Stocks Under $100 to Buy Now. Mark Altschwager, an analyst at Baird, raised the price target for Urban Outfitters, Inc. (NASDAQ:URBN) to $90 from $75, while elevating the rating from 'Neutral' to 'Outperform'. This price appreciation of 20% underscores the company's position for a turnaround. The company recently reported strong first-quarter results, with a 74% increase in net income stemming from margin improvement. The investors are closely monitoring the giant's subscription/rental business, Nuuly, which is anticipated to grow 43% to $540m this year. A frontline retail worker organizing apparel products in a store. To sum it up, Urban Outfitters, Inc. (NASDAQ:URBN) is a unique 'growth at a reasonable price' stock that is witnessing strong comp sales growth in each of its brands, and with even more room to grow via both price hikes and traffic increases. As long as the company is able to capitalize on Nuuly, we can expect it to show sustained momentum. Urban Outfitters, Inc. (NASDAQ:URBN) is a Pennsylvania-based fashion business that operates through three segments: Retail, Wholesale, and Subscription. Incepted in 1970, the company serves its customers directly through websites and retail stores, as well as social media and external sources. While the broader market delivered nearly 100% return in five years, URBN has exhibited a return of 295%. While we acknowledge the potential of URBN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
29 minutes ago
- Yahoo
Famed analysts and investors have been putting their names on ETFs. Here's what it takes for a fund to succeed.
ETF launches continue to surge, with some popular market voices putting their names on funds. Starting an ETF involves significant expenses, including SEC filing and listing fees. Funds need strong performance and substantial assets under management to remain viable. A string of widely followed strategists, economists, and investors have launched exchange-traded funds in recent years. There's famed NYU professor Nouriel Roubini — known colloquially as "Dr. Doom" — and his Atlas America Fund (USAF). Then there's Dan Ives — the tech and AI permabull who can often be found on CNBC wearing fluorescent blazers — who has parlayed his bold analyst calls into the Wedbush AI Revolution ETF (IVES). And let's not forget Fundstrat's Tom Lee — former chief equity strategist at JPMorgan — and his Granny Shots US Large Cap ETF (GRNY). They've stepped into a crowded market with thousands of funds competing for investors' money. A record 723 ETFs came to market in 2024 alone. And they're using their own high-profile personal brands to stand out in a crowded marketplace. But starting a fund is an entirely different beast than keeping one afloat for any sustained amount of time. Yes, strong performance is crucial. But running a fund is expensive, and it takes much more than good returns to ensure success. To start, the cost to launch a fund is hefty. Firms are looking at a $50,000-to-$100,000 filing fee with the SEC, according to Zachary Evans, analyst for passive strategies at Morningstar. puts that number between $100,000 and $500,000. Depending on the type of fund, there also may be an initial listing fee with NYSE or Nasdaq. But the bills don't stop there. Listing fees with the exchange come due every year. With Nasdaq, for example, it's a $4,000 annual fee. Then there's a long list of costs associated with running the fund itself, Evans said. Paying the staff who execute the trades. Paying compliance and a risk-management team. Paying sales and advertising teams to market the fund. Paying rent for your office space. And so on. It all adds up, and it means funds need to amass significant assets under management. ETF providers make money through the annual fees, or expense ratios, they charge investors. So the more money they manage, the more money they're bringing in. Performance also plays a role here — if a fund's value rises by 20% in a year, the fees it extracts will be 20% higher. "This can vary quite a bit, but a baseline number we've heard is that it should cost around $200,000 a year to run an ETF," Evans told BI. "More complicated strategies will cost more, simpler strategies will cost less, or if it's from a large firm that has economies of scale, it might cost less as well." He added: "Say an ETF charges 50 basis points with annual expenses of $200,000 a year. You need $40 million AUM in order to break even on that product." For some funds, there's also pressure associated with seed money. When an ETF launches, Evans said it might have some investors who promise to keep their capital locked up in the fund for a set period of time — say two or three years. Once that period ends, if the investors pull their money, it can be an existential threat to a fund if they haven't pulled in enough money from elsewhere. "Once that seed money dries up, in order for them to endure, they need to make sure they have enough investor interest, enough assets to sustain them," Evans said. Fund closures are increasingly common. Evans said a little more than 200 closed in 2023 — a record — and just under 200 closed in 2024. "As more companies are launching their products, more companies are closing down their products — the vast majority of which have really failed to catch on with investors," Evans said. "They've failed to generate either the performance or, in effect, the asset level to support these products." Read the original article on Business Insider Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29 minutes ago
- Yahoo
Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results
Insmed Incorporated (NASDAQ:INSM) is among the 10 Best Growth Stocks Under $100 to Buy Now. The shares of Insmed Incorporated (NASDAQ:INSM) have witnessed a surge of about 32% in the course of five days following the success of Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The results were evaluated about 24 hours after the administration of the drug, showcasing a consistent benefit throughout the 24-hour dosing period. Additionally, the company has revealed plans to initiate discussions with the U.S. Food and Drug Administration (FDA) to shape its Phase 3 trials roadmap. While this first Phase 3 trial will focus on pulmonary hypertension tied to interstitial lung disease by the year's end, the second trial is designed for PAH patients in the coming year. By 2032, the global market for pulmonary arterial hypertension is set to climb to $12.2 billion. A biopharmaceutical research team taking notes in front of a laboratory's microscope. The two anticipated phase 3 studies are enough to be excited about the company, yet there exists another breakthrough. Insmed Incorporated (NASDAQ:INSM) has finalized and submitted its New Drug Application (NDA) of brensocatib for treating patients with Non-cystic fibrosis bronchiectasis (NCFBE), with the date for review set for August 12, 2025. The company is indeed among the companies with high growth potential. Insmed Incorporated (NASDAQ:INSM) is a New Jersey-based biopharmaceutical company that develops and markets therapies to treat patients with serious and rare diseases. With a global presence, the company is committed to transforming the lives of many. While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
